Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss

  title={Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss},
  author={A. Yassin and Gheorge Doros},
  journal={Clinical Obesity},
  pages={73 - 83}
Hypogonadism is associated with increased fat mass and reduced muscle mass, which contributes to obesity and health risks, such as cardiovascular disease. Testosterone treatment of hypogonadal men improves muscle mass and reduces fat mass; however, many of these studies are of short duration. Thus, the long‐term effects of testosterone on body anthropometry are not known. 

Glycemic benefits with adherence to testosterone therapy in men with hypogonadism and type 2 diabetes mellitus

Even when controlling for improved BMI, pre-treatment A1C, and age, testosterone positively impacted glycemic control in diabetes patients with hypogonadism, with the most benefit noted in those most adherent to therapy (>75%).

Metabolic syndrome and hypogonadism--two peas in a pod.

An account of the pathophysiological mechanisms in the bidirectional relationship between hypogonadism and body composition, inflammation and insulin sensitivity as well as the effects of testosterone replacement on diverse metabolic parameters are provided.

Effects of Testosterone Replacement Therapy on Cardio-Metabolic, Hormonal and Anthropometric Parameters in Obese Hypogonadal Men with Metabolic Syndrome

Study showed favorable effects of testosterone replacement in aging patients with low testosterone levels, and improves cardio-metabolic and hormonal parameters, and has a positive impact on patient body weight, favorable safety profile and high level of patient tolerability.

Testosterone and weight loss: the evidence

  • A. Traish
  • Medicine, Biology
    Current opinion in endocrinology, diabetes, and obesity
  • 2014
Analysis of contemporary data linking testosterone therapy in overweight and obese men with testosterone deficiency to increased lean body mass, decreased fat mass, improvement in overall body composition and sustained weight loss shows that testosterone therapy ameliorates components of the metabolic syndrome.

Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.

Long-term TU treatment resulted in a sustained improvement in erectile function and muscle and joint pain, which contributed to an improvement in long-term health-related quality of life.

Secondary male hypogonadism: a prevalent but overlooked comorbidity of obesity

Weight loss and treatment to replace testosterone levels improve the metabolic profile and quality of life in patients with obesity and hypogonadism; these beneficial effects depend on treatment modality and duration of therapy.

Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy

Three factors were significantly associated with sustained weight loss over the entire period of TU treatment: a loss of 3% of the baseline body weight after 1 year of TRT, baseline BMI over 30 and a waist circumference >102 cm.



Long‐term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss

This study analyzed the effects of normalization of serum testosterone (T) levels on anthropometric parameters in hypogonadal men and found no significant differences in the values of these parameters between men with and without a history of substance abuse.

Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double‐blinded placebo‐controlled Moscow study

The aim of this study was to establish whether the normalization of plasma T improves the features of the MetS.

Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review

While overall treatment of obesity is unsuccessful, T treatment of hypogonadal men may be effective, also because it improves mood, energy, reduces fatigue and may motivate men to adhere to diet and exercise regimens designed to combat obesity.

Testosterone and cardiovascular disease: an old idea with modern clinical implications.

Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?

  • F. Saad
  • Medicine, Biology
    Diabetes/metabolism research and reviews
  • 2012
It is suggested that T may have the potential to decrease CVD risk in men with androgen deficiency by focusing on evidence derived from three different approaches.

Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy

Objective  Androgen deprivation therapy (ADT) for prostate cancer is associated with increases in fat mass and risk of type 2 diabetes; however, the relationship between sex steroid deficiency and

Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip

Testosterone treatment improved body composition, but it did not reverse the unfavorable metabolic profile, and bone mineral density in the hip was significantly higher after the testosterone treatment.

Testosterone deficiency.

The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.

  • P. MårinS. Holmäng P. Björntorp
  • Medicine, Biology
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1992
It is concluded that testosterone treatment of middle-aged abdominally obese men gives beneficial effects on well-being and the cardiovascular and diabetes risk profile, results similar to those observed after hormonal replacement therapy in postmenopausal women.

Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.

Testosterone therapy, relative to placebo, selectively lessened visceral fat accumulation without change in total body FM and increased total body FFM and total body and thigh skeletal muscle mass.